{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:46:41Z","timestamp":1793422001183,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jpba.2025.117298","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:12:25Z","timestamp":1764868345000},"page":"117298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A universal LC-HRMS workflow integrating targeted and untargeted strategies for rapid and comprehensive metabolite profiling of oligonucleotide-based therapeutics"],"prefix":"10.1016","volume":"270","author":[{"given":"Yuqing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-4355","authenticated-orcid":false,"given":"Chongzhuang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jpba.2025.117298_bib1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA drugs and RNA targets for small molecules: principles, progress, and challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.jpba.2025.117298_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9062004","article-title":"Antisense Oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.jpba.2025.117298_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jpba.2007.01.042","article-title":"Application of LC\u2013MS for quantitative analysis and metabolite identification of therapeutic oligonucleotides","volume":"44","author":"Lin","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"24","key":"10.1016\/j.jpba.2025.117298_bib4","doi-asserted-by":"crossref","first-page":"15474","DOI":"10.3390\/ijms232415474","article-title":"Bioanalysis of Oligonucleotide by LC-MS: effects of ion pairing regents and recent advances in ion-pairing-free analytical strategies","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jpba.2025.117298_bib5","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/dmd.121.000417","article-title":"Absorption, distribution, metabolism, and excretion of US Food and Drug Administration\u2013Approved ANtisense Oligonucleotide Drugs","volume":"50","author":"Migliorati","year":"2022","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jpba.2025.117298_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","article-title":"Therapeutic Oligonucleotides: state of the art","volume":"59","author":"Smith","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.jpba.2025.117298_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4839","article-title":"metabolism of 2\u2032-ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometry","volume":"34","author":"Kim","year":"2020","journal-title":"Biomed. Chromatogr."},{"issue":"10","key":"10.1016\/j.jpba.2025.117298_bib8","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.drudis.2021.04.002","article-title":"Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates","volume":"26","author":"Weidolf","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.jpba.2025.117298_bib9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.jpba.2025.117298_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.coph.2005.07.001","article-title":"Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers","volume":"5","author":"Amantana","year":"2005","journal-title":"Curr. Opin. Pharm."},{"issue":"6","key":"10.1016\/j.jpba.2025.117298_bib11","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1208\/s12248-017-0088-2","article-title":"Characterization of Apolipoprotein C3 (Apo C3) LNA\/DNA Impurities and Degradation Products by LC-MS\/MS","volume":"19","author":"Friese","year":"2017","journal-title":"AAPS J."},{"issue":"12","key":"10.1016\/j.jpba.2025.117298_bib12","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1124\/dmd.124.001819","article-title":"Characterization of nonclinical drug metabolism and pharmacokinetic properties of phosphorodiamidate morpholino oligonucleotides, a novel drug class for Duchenne muscular dystrophy","volume":"52","author":"Goey","year":"2024","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.jpba.2025.117298_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ymthe.2020.11.008","article-title":"Pharmacokinetics and proceedings in clinical application of nucleic acid therapeutics","volume":"29","author":"Herkt","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jpba.2025.117298_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.31","article-title":"Elucidation of the biotransformation pathways of a Galnac3-conjugated Antisense Oligonucleotide in rats and monkeys","volume":"5","author":"Shemesh","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"6","key":"10.1016\/j.jpba.2025.117298_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.121.000428","article-title":"The nonclinical disposition and pharmacokinetic\/pharmacodynamic properties of N-Acetylgalactosamine\u2013Conjugated small interfering rna are highly predictable and build confidence in translation to human","volume":"50","author":"McDougall","year":"2022","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.jpba.2025.117298_bib16","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/s41565-024-01785-0","article-title":"Direct cytosolic delivery of siRNA via cell membrane fusion using cholesterol-enriched exosomes","volume":"19","author":"Zhuo","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"17","key":"10.1016\/j.jpba.2025.117298_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26175420","article-title":"Chemistry of peptide-oligonucleotide conjugates: a review","volume":"26","author":"Klabenkova","year":"2021","journal-title":"Molecules"},{"issue":"24","key":"10.1016\/j.jpba.2025.117298_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245963","article-title":"Cellular targeting of oligonucleotides by conjugation with small molecules","volume":"25","author":"Hawner","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.jpba.2025.117298_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/dmd.122.001135","article-title":"Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools","volume":"51","author":"Cai","year":"2023","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.jpba.2025.117298_bib20","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/rcm.3561","article-title":"Metabolite identification of small interfering RNA duplex by high-resolution accurate mass spectrometry","volume":"22","author":"Zou","year":"2008","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"6","key":"10.1016\/j.jpba.2025.117298_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100089","article-title":"Comparative metabolism of an N-acetylgalactosamine\u2013conjugated small interfering RNA, inclisiran, among various in vitro systems and correlations with in vivo metabolism in rats","volume":"53","author":"Zhang","year":"2025","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2025.117298_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2025.124505","article-title":"Automatic identification of oligonucleotide metabolites in complex biological samples using ultra high-performance liquid chromatography high-resolution mass spectrometry combined with the molecule profiler software","volume":"1254","author":"Ye","year":"2025","journal-title":"J. Chromatogr. B"},{"issue":"6","key":"10.1016\/j.jpba.2025.117298_bib23","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00216-015-9266-1","article-title":"Development of a method based on ultra high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry for studying the in vitro metabolism of phosphorothioate oligonucleotides","volume":"408","author":"Studzi\u0144ska","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"issue":"12","key":"10.1016\/j.jpba.2025.117298_bib24","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1021\/acs.analchem.7b01244","article-title":"Identification of GalNAc-conjugated antisense oligonucleotide metabolites using an untargeted and generic approach based on high resolution mass Spectrometry","volume":"89","author":"Husser","year":"2017","journal-title":"Anal. Chem."},{"issue":"10","key":"10.1016\/j.jpba.2025.117298_bib25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1124\/dmd.123.001370","article-title":"In Vivo Metabolite Profiles of an N-Acetylgalactosamine\u2013Conjugated Antisense Oligonucleotide AZD8233 using liquid chromatography high-resolution mass spectrometry: a cross-species comparison in animals and humans","volume":"51","author":"Li","year":"2023","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.jpba.2025.117298_bib26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1208\/s12248-012-9394-x","article-title":"A one-step solid phase extraction method for bioanalysis of a Phosphorothioate Oligonucleotide and Its 3\u2032 n-1 metabolite from rat plasma by uHPLC\u2013MS\/MS","volume":"14","author":"Chen","year":"2012","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.jpba.2025.117298_bib27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/jms.1390","article-title":"An algorithm for thorough background subtraction from high-resolution LC\/MS data: application for detection of glutathione-trapped reactive metabolites","volume":"43","author":"Zhang","year":"2008","journal-title":"J. Mass Spectrom."},{"issue":"21","key":"10.1016\/j.jpba.2025.117298_bib28","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.4155\/bio-2019-0137","article-title":"Oligonucleotide Quantification and Metabolite Profiling by High-Resolution and Accurate Mass Spectrometry","volume":"11","author":"Liu","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2025.117298_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462184","article-title":"Analytical characterization of DNA and RNA oligonucleotides by hydrophilic interaction liquid chromatography-tandem mass spectrometry","volume":"1648","author":"Huang","year":"2021","journal-title":"J. Chromatogr. A"},{"issue":"4","key":"10.1016\/j.jpba.2025.117298_bib30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mas.21641","article-title":"Bioanalysis and Biotransformation of Oligonucleotide Therapeutics by Liquid Chromatography-Mass Spectrometry","volume":"40","author":"Sutton","year":"2020","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpba.2025.117298_bib31","first-page":"73","article-title":"High-resolution mass spectrometry-based data acquisition and data-mining technologies for detecting and characterizing drug metabolites and traditional Chinese medicine components","author":"Cai","year":"2020","journal-title":"Identif. Quantif. Drugs Metab. Drug Metab. Enzym. Transp."},{"issue":"9","key":"10.1016\/j.jpba.2025.117298_bib32","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/jms.1432","article-title":"An algorithm for thorough background subtraction from high-resolution LC\/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine","volume":"43","author":"Zhang","year":"2008","journal-title":"J. Mass Spectrom."},{"issue":"2","key":"10.1016\/j.jpba.2025.117298_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1389200223666220211093548","article-title":"Recent Progress on Mass Spectrum Based Approaches for Absorption, Distribution,Metabolism, and Excretion Characterization of Traditional Chinese Medicine","volume":"23","author":"Bai","year":"2022","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jpba.2025.117298_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104935","article-title":"Artificial intelligence and network pharmacology based investigation of pharmacological mechanism and substance basis of Xiaokewan in treating diabetes","volume":"159","author":"Zhu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jpba.2025.117298_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.aca.2016.09.034","article-title":"Untargeted screening of unknown xenobiotics and potential toxins in plasma of poisoned patients using high-resolution mass spectrometry: Generation of xenobiotic fingerprint using background subtraction","volume":"944","author":"Chen","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2025.117298_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114583","article-title":"Suspect screening and untargeted analysis of veterinary drugs in food by LC-HRMS: application of background exclusion-dependent acquisition for retrospective analysis of unknown xenobiotics","volume":"210","author":"Zhu","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"11","key":"10.1016\/j.jpba.2025.117298_bib37","doi-asserted-by":"crossref","first-page":"11249","DOI":"10.1021\/acsnano.4c18924","article-title":"Direct Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Neovascularization","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.jpba.2025.117298_bib38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525006399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525006399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:58:37Z","timestamp":1767945517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525006399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S0731708525006399"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117298","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A universal LC-HRMS workflow integrating targeted and untargeted strategies for rapid and comprehensive metabolite profiling of oligonucleotide-based therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117298"}}